USO 21507
A Phase III, Open-label, Randomized Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent, Inoperable or Metastatic Triple-negative Breast Cancer D926PC00001: (TROPION Breast02).
Disease Types: Breast Cancer Research
Available at:
- Chesapeake
- Newport News (Port Warwick III)
- Norfolk (Brock Cancer Center)
- Virginia Beach (Princess Anne)